Lakota J, Skultety L, Dubrovcakova M, Altaner C
Bone Marrow Transplantation Unit, National Cancer Institute, Bratislava.
Neoplasma. 2008;55(6):488-92.
Here we report patients with Hodgkin's disease and multiple myeloma, who relapsed/progressed after high dose therapy and autologous stem cell transplantation. In patients who developed aplastic anemia type syndrome, spontaneous tumor regression was observed and concomitantly high titers of serum autoantibodies were found. In order to identify the antibody specificity, two-dimensional electrophoresis, blotting and immunoreactions were used to analyze the peripheral blood stem cell extract with autoantibodies containing serum. The unique protein spot visualized exclusively by serum of patients with aplastic anemia type syndrome was identified as carbonic anhydrase I (CA I, accession No. P00915 and Q7M316) by means of mass spectrometry. The specificity of autoantibodies was confirmed by reaction with commercial CAs I, II, IX and XII. Immunoreaction in Western blots with these CA isoforms differed in sera obtained from patients with various types of the disease. Sera of Hodgkin's disease patients reacted with CA I, II and XII; sera of multiple myeloma patients reacted with the CA I, II, XII and IX. Patients developing and/or possessing CA autoantibodies had a significant survival benefit over those who did not develop CA anhydrase autoantibodies. Possible relevance of the presence of CA autoantibodies and clinical outcome is discussed.
在此，我们报告了患有霍奇金淋巴瘤和多发性骨髓瘤的患者，他们在接受高剂量治疗和自体干细胞移植后复发/病情进展。在发生再生障碍性贫血样综合征的患者中，观察到肿瘤自发消退，同时发现血清自身抗体滴度很高。为了确定抗体特异性，采用二维电泳、印迹和免疫反应，用含有自身抗体的血清分析外周血干细胞提取物。通过质谱分析，再生障碍性贫血样综合征患者血清特异地显示出的独特蛋白质斑点被鉴定为碳酸酐酶I（CA I，登录号P00915和Q7M316）。通过与商品化的CA I、II、IX和XII反应，证实了自身抗体的特异性。在Western印迹中，这些CA同工型与不同疾病类型患者血清的免疫反应不同。霍奇金淋巴瘤患者的血清与CA I、II和XII反应；多发性骨髓瘤患者的血清与CA I、II、XII和IX反应。产生和/或拥有CA自身抗体的患者比未产生CA无水酶自身抗体的患者有显著的生存获益。本文讨论了CA自身抗体的存在与临床结果之间可能的相关性。
